Approval · Notice of Compliance 19730 · 2017
STIVARGA: Notice of Compliance 19730
Issued August 29, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19730
- Date
- August 29, 2017
- Company
- Bayer Inc.Elkhart, Indiana, United States
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Modification to the indication for metastatic colorectal cancer (mcrc) to change the 'kras wild type' specification to 'ras wild type' in patients previously treated for anti egfr therapy
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| STIVARGA | Not yet assigned | — |
Medicinal ingredients
- REGORAFENIB 40 MG per TAB